Annals of Diagnostic Pathology
Volume 10, Issue 5 , Pages 263-268 , October 2006

Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation

  • Malisha R. Johnson, DO

      Affiliations

    • Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Daniel Del Carpio-Jayo, MD

      Affiliations

    • Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Pei Lin, MD

      Affiliations

    • Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Sergio Giralt, MD

      Affiliations

    • Department of Bone Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Paolo Anderlini, MD

      Affiliations

    • Department of Bone Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Richard E. Champlin, MD

      Affiliations

    • Department of Bone Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Issa F. Khouri, MD

      Affiliations

    • Department of Bone Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Saroj Vadhan-Raj, MD

      Affiliations

    • Department of Cytokine and Supportive Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • L. Jeffrey Medeiros, MD

      Affiliations

    • Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Carlos E. Bueso-Ramos, MD, PhD

      Affiliations

    • Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 713 792 6328; fax: +1 713 794 1800.

References 

  1. Dimopoulos MA, Palumbo A, Delasalle KB, et al. Primary plasma cell leukaemia. Br J Haematol. 1994;88:754–759
  2. International Myeloma Working Group . Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757
  3. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med. 1974;133:813–818
  4. Woodruff RK, Malpas JS, Paxton AM, et al. Plasma cell leukemia (PCL): a report on 15 patients. Blood. 1978;52:839–845
  5. Kosmo MA, Gale RP. Plasma cell leukemia. Semin Hematol. 1987;24:202–208
  6. Saccaro S, Fonseca R, Veillon DM, et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol. 2005;78:288–294
  7. Costello R, Sainty D, Bouabdallah R, et al. Primary plasma cell leukaemia: a report of 18 cases. Leuk Res. 2001;25:103–107
  8. Chang H, Sloan S, Li D, et al. Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. Cancer Genet Cytogenet. 2005;156:150–153
  9. Bernasconi C, Castelli G, Pagnucco G, et al. Plasma cell leukemia: a report on 15 patients. Eur J Haematol Suppl. 1989;51:76–83
  10. Castellano-Sanchez AA, Kreisel FH. Pathologic quiz case: a 39-year-old man with severe lower back pain. Plasma cell leukemia. Arch Pathol Lab Med. 2005;129:e70–e72
  11. Hovenga S, de Wolf JT, Klip H, et al. Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature. Bone Marrow Transplant. 1997;20:901–904
  12. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032–1037
  13. Panizo C, Rifon J, Rodriguez–Wilhelmi P, et al. Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood stem cell transplantation and interferon-alpha. Acta Haematol. 1999;101:193–196
  14. Vela-Ojeda J, Garcia-Ruiz Esparza MA, Rosas-Cabral A, et al. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol. 2002;81:362–367
  15. Avet–Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood. 2001;97:822–825
  16. Hayman SR, Fonseca R. Plasma cell leukemia. Curr Treat Options Oncol. 2001;2:205–216
  17. Gemmel C, Cremer FW, Weis M, et al. Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Ann Hematol. 2002;81:119–123
  18. Byrne JL, Fairbairn J, Davy B, et al. Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission. Bone Marrow Transplant. 2003;31:157–161
  19. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med. 1987;83:1062–1068
  20. Sica S, Chiusolo P, Salutari P, et al. Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologous peripheral blood progenitor cell transplant: molecular follow-up of minimal residual disease. Bone Marrow Transplant. 1998;22:823–825
  21. Schlette E, Medeiros LJ, Keating M, et al. CD79b expression in chronic lymphocytic leukemia. Association with trisomy 12 and atypical immunophenotype. Arch Pathol Lab Med. 2003;127:561–566
  22. Mansoor A, Medeiros LJ, Weber DM, et al. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol. 2001;116:543–549
  23. Perez-Andres M, Almeida J, Martin-Ayuso M, et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia. 2005;19:449–455
  24. Mattioli M, Agnelli L, Fabris S, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene. 2005;24:2461–2473
  25. Hogan WFR, Rajkumar V, et al. Plasma cell leukemia: long term follow-up information. Proc Annu Meet Am Soc Clin Oncol. 1999;18:A109;[abstr]
  26. Mateo G, Castellanos M, Rasillo A, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res. 2005;11:3661–3667

PII: S1092-9134(05)00218-2

doi: 10.1016/j.anndiagpath.2005.12.011

Annals of Diagnostic Pathology
Volume 10, Issue 5 , Pages 263-268 , October 2006

Article Tools

* Image Usage & Resolution